Stroke is a serious problem in the United States, especially alongside atrial fibrillation, as the chances of suffering a stroke increase five-fold. As it is responsible for 90% of clot formation for ischemic stroke, there is a definitive clinical need that utilizes left atrial appendage functions, while reducing stroke rates.
Our implant does not come with bleeding risks associated with long-term use of warfarin. Occulsion devices offer additional options to warfarin, but by closing off the appendage, there is a decrease in hormone secretion which regulates blood pressure. Our solution uses US-patent protected technology to address non-valvular atrial fibrillation to effectively reduce your risk of stroke. This technology has potential to offer patients a life-changing treatment superior to anti-coagulation medication and occlusion devices.